Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.

doi:10.1038/s41591-024-02942-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.

Nature medicine - 1 May 2024

Friedman Claire F, Manning-Geist Beryl L, Zhou Qin, Soumerai Tara, Holland Aliya, Da Cruz Paula Arnaud, Green Hunter, Ozsoy Melih Arda, Iasonos Alexia, Hollmann Travis, Leitao Mario M, Mueller Jennifer J, Makker Vicky, Tew William P, O'Cearbhaill Roisin E, Liu Ying L, Rubinstein Maria M, Troso-Sandoval Tiffany, Lichtman Stuart M, Schram Alison, Kyi Chrisann, Grisham Rachel N, Causa Andrieu Pamela, Wherry E John, Aghajanian Carol, Weigelt Britta, Hensley Martee L, Zamarin Dmitriy

Abstract excerpt

Programmed death-1 (PD-1) inhibitors are approved for therapy of gynecologic cancers with DNA mismatch repair deficiency (dMMR), although predictors of response remain elusive. We conducted a single-arm phase 2 study of nivolumab in 35 patients with dMMR uterine or ovarian cancers. Co-primary endpoints included objective response rate (ORR) and progression-free survival at 24 weeks (PFS24). Secondary endpoints...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to DNA Mismatch Repair

Share to Genital Neoplasms, Female

Share to Nivolumab

Share to Ovarian Neoplasms

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 38653864
DOI: 10.1038/s41591-024-02942-7
PMCID: PMC11108776

Genes

MEGF8
SETD1B
TOX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.PMID 38653864Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial CarcinomaSemantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacySemantic proximity Read ↗

Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).Semantic proximity Read ↗

DNA Repair Deficiency and Immunotherapy ResponseSemantic proximity Read ↗

Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of CareSemantic proximity Read ↗

Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation SequencingSemantic proximity Read ↗

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advancesSemantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studySemantic proximity Read ↗

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.